Keyphrases
Ustekinumab
100%
Crohn's Disease
100%
Inflammatory Bowel Disease
100%
Fistulization
57%
Persistence Rate
42%
Ulcerative Colitis
42%
Nave
28%
Cox Proportional Hazards Model
28%
Disease Groups
28%
All Diseases
28%
Hazard Ratio
14%
Confidence Interval
14%
Adult Patients
14%
Multivariable
14%
Canada
14%
Patient Characteristics
14%
Stratified Analysis
14%
Kaplan-Meier Method
14%
Real-world Effectiveness
14%
Large Population
14%
Treatment Response
14%
Crohn's Colitis
14%
Patient Support
14%
Surrogate Measures
14%
High Persistence
14%
Long-term Persistence
14%
Treatment Persistence
14%
Perianal Crohn's Disease
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ustekinumab
100%
Crohn's Disease
100%
Inflammatory Bowel Disease
100%
Ulcerative Colitis
50%
Disease
25%
Biological Product
12%
Retrospective Study
12%
Immunology and Microbiology
Crohn's Disease
100%
Inflammatory Bowel Disease
100%
Ustekinumab
100%
Ulcerative Colitis
50%
Biological Product
12%